Stem Cell Cures

 

With new technology, Green Cross is expanding its business in China, following its expansion to the North American market, which is the largest pharmaceutical market in the world. 

On March 6, Green Cross signed an MOU with the Guizhou Province in China for investment in a project related to cell cures. Under the agreement, the company will invest in order to produce and distribute the cell cure products in China. 

The MOU was possible, since the interests of both Green Cross and Guizhou Province corresponded. Green Cross has been trying to tap the global cell treatment market, while Guizhou Province has been trying to attract investment from overseas companies to establish a specialized biotechnology complex. 

There is a positive outlook, considering the fact that Green Cross has already been carrying on a plasma derivatives businesses for 20 years in China and improved its brand awareness. Also, the company is well aware of the local business conditions. 

According to global consulting firm McKinsey & Company, the Chinese pharmaceutical market, the 3rd largest in the world, has seen an average annual growth rate of 21 percent in the last 5 years.

By 2020, the market is expected to continue to grow 17 prevent every year, becoming the 2nd largest pharmaceutical market in the world, and ultimately rank first in the future.

Green Cross is planning to enter the Chinese market, focusing on immune cell treatments at the beginning, and gradually expand its business field to stem cell cures.

Copyright © BusinessKorea. Prohibited from unauthorized reproduction and redistribution